U.S. Intravenous Solutions Market
Description
U.S. Intravenous Solutions Market Size, Share & Trends Analysis Report By Type (Total Parenteral Nutrition (TPN), Peripheral Parenteral Nutrition (PPN)), By Nutrients (Carbohydrates, Vitamins & Minerals, Single-dose Amino Acids), And Segment Forecasts, 2026 - 2033
U.S. Intravenous Solutions Market Summary
The U.S. intravenous solutions market size was estimated at USD 4.9 billion in 2025 and is projected to reach USD 9.8 billion by 2033, growing at a CAGR of 9.4% from 2026 to 2033. The market growth is driven by an aging population needing medical interventions, a surge in chronic diseases requiring advanced treatments, and enhancements in healthcare technology that elevate patient care.
This sector's growth reflects the critical need for innovative healthcare solutions to address the complex demands of modern medicine. The increasing incidence of cancer is a key driver for the U.S. intravenous solutions industry, as cancer patients frequently require IV therapy for chemotherapy administration, hydration, electrolyte balance, and supportive care. For instance, the American Cancer Society estimated that in 2026, around 60,480 new cases of oral cavity or oropharyngeal cancer and about 13,150 related deaths will be recorded, highlighting the growing patient pool requiring continuous IV-based treatment and nutritional support.
The rising use of immunonutrition formulas is driving growth in the U.S. IV solutions market, particularly in post-surgical recovery and critical care settings. These specialized parenteral formulations are designed to enhance immune response, reduce infection risk, and improve clinical outcomes in trauma, surgical, and critically ill patients. Products such as Elemune by Otsuka Holdings Co., Ltd., which contains L-alanyl-L-glutamine, are widely used for metabolic and immune support in infection and trauma cases. Similarly, SMOFlipid and Omegaven by Fresenius Kabi AG provide lipid-based nutrition enriched with omega-3 fatty acids, supporting energy requirements and reducing inflammation in ICU patients with limited enteral feeding. The growing clinical emphasis on improved recovery outcomes and reduced hospital stays is driving the adoption of advanced IV nutritional solutions across U.S. healthcare settings.
U.S. Intravenous Solutions Market Report Segmentation
This report forecasts revenue & volume growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. intravenous solutions market report based on type, nutrients, and end use:
U.S. Intravenous Solutions Market Summary
The U.S. intravenous solutions market size was estimated at USD 4.9 billion in 2025 and is projected to reach USD 9.8 billion by 2033, growing at a CAGR of 9.4% from 2026 to 2033. The market growth is driven by an aging population needing medical interventions, a surge in chronic diseases requiring advanced treatments, and enhancements in healthcare technology that elevate patient care.
This sector's growth reflects the critical need for innovative healthcare solutions to address the complex demands of modern medicine. The increasing incidence of cancer is a key driver for the U.S. intravenous solutions industry, as cancer patients frequently require IV therapy for chemotherapy administration, hydration, electrolyte balance, and supportive care. For instance, the American Cancer Society estimated that in 2026, around 60,480 new cases of oral cavity or oropharyngeal cancer and about 13,150 related deaths will be recorded, highlighting the growing patient pool requiring continuous IV-based treatment and nutritional support.
The rising use of immunonutrition formulas is driving growth in the U.S. IV solutions market, particularly in post-surgical recovery and critical care settings. These specialized parenteral formulations are designed to enhance immune response, reduce infection risk, and improve clinical outcomes in trauma, surgical, and critically ill patients. Products such as Elemune by Otsuka Holdings Co., Ltd., which contains L-alanyl-L-glutamine, are widely used for metabolic and immune support in infection and trauma cases. Similarly, SMOFlipid and Omegaven by Fresenius Kabi AG provide lipid-based nutrition enriched with omega-3 fatty acids, supporting energy requirements and reducing inflammation in ICU patients with limited enteral feeding. The growing clinical emphasis on improved recovery outcomes and reduced hospital stays is driving the adoption of advanced IV nutritional solutions across U.S. healthcare settings.
U.S. Intravenous Solutions Market Report Segmentation
This report forecasts revenue & volume growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. intravenous solutions market report based on type, nutrients, and end use:
- Type Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
- Total Parenteral Nutrition
- Peripheral Parenteral Nutrition
- Nutrients Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
- Carbohydrates
- Vitamins & Minerals
- Single-dose Amino Acids
- Parenteral Lipid Emulsion
- Others
- End Use Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
- Home
- Hospitals
- Infusion Centers
Table of Contents
80 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Nutrient
- 1.2.3. End use
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Aging Population and Higher Hospitalization Rates
- 3.2.1.2. Increasing Surgical Procedures and Critical Care Admissions
- 3.2.1.3. Rising Prevalence of Chronic Diseases
- 3.2.1.4. Growth of Home Infusion and Outpatient Care
- 3.2.1.5. Increasing adoption of immuno-nutrition formulas
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Shortage of Parenteral Nutrition Products
- 3.2.2.2. High Risk of Infections
- 3.2.3. Industry Opportunity Analysis
- 3.2.4. Industry Challenge Analysis
- 3.2.5. Regulatory Framework
- 3.2.5.1. Standards and Compliances
- 3.2.5.1.1. North America
- 3.2.5.1.2. Europe
- 3.2.5.1.3. Asia Pacific
- 3.2.5.1.4. Latin America
- 3.2.5.1.5. MEA
- 3.3. Business Environment Analysis
- 3.3.1. Porter’s Five Forces Analysis
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTLE Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic and Social landscape
- 3.3.2.3. Technological landscape
- 3.3.2.4. Environmental landscape
- 3.3.2.5. Legal Landscape
- Chapter 4. Intravenous Solutions Market: Product Estimates & Trend Analysis
- 4.1. Product Segment Dashboard
- 4.2. Product Market Share Movement Analysis, 2025 & 2033
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (Volume, Thousand Units, Revenue USD Million)
- 4.4. Total Parenteral Nutrition
- 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Volume, Thousand Units, Revenue USD Million)
- 4.5. Peripheral Parenteral Nutrition
- 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Volume, Thousand Units, Revenue USD Million)
- Chapter 5. Intravenous Solutions Market: Nutrient Estimates & Trend Analysis
- 5.1. Nutrient Segment Dashboard
- 5.2. Nutrient Market Share Movement Analysis, 2025 & 2033
- 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (Volume, Thousand Units, Revenue USD Million)
- 5.4. Carbohydrates
- 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Volume, Thousand Units, Revenue USD Million)
- 5.5. Vitamins & Minerals
- 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Volume, Thousand Units, Revenue USD Million)
- 5.6. Single-dose Amino Acids
- 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Volume, Thousand Units, Revenue USD Million)
- 5.7. Parenteral Lipid Emulsion
- 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 Volume, Thousand Units, Revenue USD Million)
- 5.8. Others
- 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Volume, Thousand Units, Revenue USD Million)
- Chapter 6. Intravenous Solutions Market: End Use Estimates & Trend Analysis
- 6.1. End Use Segment Dashboard
- 6.2. End Use Market Share Movement Analysis, 2025 & 2033
- 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (Volume, Thousand Units, Revenue USD Million)
- 6.4. Home
- 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Volume, Thousand Units, Revenue USD Million)
- 6.5. Hospitals
- 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Volume, Thousand Units, Revenue USD Million)
- 6.6. Infusion Centers
- 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (Volume, Thousand Units, Revenue USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Company Market Position Analysis, 2025
- 7.2. Company Market Share Analysis, 2025
- 7.3. Company Categorization
- 7.4. Company Profiles/Listing
- 7.4.1. Fresenius Kabi AG
- 7.4.1.1. Overview
- 7.4.1.2. Financial performance
- 7.4.1.3. Product benchmarking
- 7.4.1.4. Strategic initiatives
- 7.4.2. B. Braun SE
- 7.4.2.1. Overview
- 7.4.2.2. Financial performance
- 7.4.2.3. Product benchmarking
- 7.4.2.4. Strategic initiatives
- 7.4.3. Baxter
- 7.4.3.1. Overview
- 7.4.3.2. Financial performance
- 7.4.3.3. Product benchmarking
- 7.4.3.4. Strategic initiatives
- 7.4.4. Otsuka Pharmaceutical Co., Ltd.
- 7.4.4.1. Overview
- 7.4.4.2. Financial performance
- 7.4.4.3. Product benchmarking
- 7.4.4.4. Strategic initiatives
- 7.4.5. Pfizer, Inc.
- 7.4.5.1. Overview
- 7.4.5.2. Financial performance
- 7.4.5.3. Product benchmarking
- 7.4.5.4. Strategic initiatives
- 7.4.6. JW Life Science
- 7.4.6.1. Overview
- 7.4.6.2. Financial performance
- 7.4.6.3. Product benchmarking
- 7.4.6.4. Strategic initiatives
- 7.4.7. CSL Vifor (formerly Vifor Pharma)
- 7.4.7.1. Overview
- 7.4.7.2. Financial performance
- 7.4.7.3. Product benchmarking
- 7.4.7.4. Strategic initiatives
- 7.4.8. ICU Medical, Inc.
- 7.4.8.1. Overview
- 7.4.8.2. Financial performance
- 7.4.8.3. Product benchmarking
- 7.4.8.4. Strategic initiatives
- 7.4.9. Amphastar Pharmaceuticals, Inc.
- 7.4.9.1. Overview
- 7.4.9.2. Financial performance
- 7.4.9.3. Product benchmarking
- 7.4.9.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


